Harvard Management Company’s AbCellera Biologics ABCL Stock Holding History

Harvard Management Company’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,105,095	Closed	-$31M	–	34
2023 Q1	$31M	Hold	4,105,095	–	–	3.25%	5
2022 Q4	$41.6M	Hold	4,105,095	–	–	5.16%	5
2022 Q3	$40.6M	Hold	4,105,095	–	–	5.05%	4
2022 Q2	$43.7M	Hold	4,105,095	–	–	5.06%	4
2022 Q1	$40M	Hold	4,105,095	–	–	4.04%	4
2021 Q4	$58.7M	Hold	4,105,095	–	–	5.51%	5
2021 Q3	$82.3M	Hold	4,105,095	–	–	4.82%	7
2021 Q2	$90.3M	Hold	4,105,095	–	–	5.2%	6
2021 Q1	$139M	Hold	4,105,095	–	–	7.79%	4
2020 Q4	$165M	Buy	+4,105,095	New	+$188M	8.96%	4

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Harvard Management Company's ABCL Position: Q2 2023 in Review

Harvard Management Company sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 4,105,095 shares — an estimated $31M sold.

Harvard Management Company first reported a position in ABCL in Q4 2020 and held it in 10 quarters. The position peaked at $165M in Q4 2020. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

Harvard Management Company reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
Harvard Management Company sold 4,105,095 AbCellera Biologics shares in Q2 2023, an estimated $31M.
Harvard Management Company first reported a position in AbCellera Biologics in Q4 2020 and held it in 10 quarters.
Harvard Management Company's AbCellera Biologics position peaked at $165M in Q4 2020.
169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Harvard Management Company's 13F filing for Q2 2023, filed 11 Aug 2023.